Wenbli has spun out the cancer and immunology programs from Prothena Biosciences, which initiated at Elan Pharmaceuticals, and our founders have over ten years of experience working with this platform of therapeutics. Our lead molecule, imaprelimab is a first in class humanized monoclonal antibody therapeutic that neutralizes a previously untargetable pathway that is shared between pathogenic immune cells in autoimmune diseases and tumor cells.